We are delighted to announce the appointment of Dr. Gaerolwe R. Masheto as the new Executive Director of the Botswana Harvard Health Partnership (BHP), effective August 8, 2025.

Dr. Masheto brings a wealth of experience and a distinguished record of leadership within BHP. He joined the BHP Clinical Trials Unit (CTU) in 2011 as a Study Physician, contributing to the successful implementation of internationally recognized clinical trials, including the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT), the Advancing Clinical Therapeutics Globally (ACTG) Network, and the HIV Prevention Trials Network (HPTN).

Over the years, he has held several key leadership roles, serving as Gaborone Clinical Research Site (CRS) Leader (2016–2022) and Molepolole CRS Leader (2020–2023). From March 2023 to August 2025, he served as Deputy Chief Executive Officer of BHP, further strengthening the institution’s research and operational capacity. He currently serves as CTU Coordinator and IMPAACT Network Project Leader/Principal Investigator (PI), while also contributing as a Co-Investigator for ACTG and HPTN studies.

Dr. Masheto holds an MD from Ross University School of Medicine (2007) and a Postgraduate Diploma in Family Medicine from Stellenbosch University (2012). He is also an alumnus of the HBNU Global Health Fellowship and the IAS Academy for Cure Research Fellowship.

His appointment marks a new chapter in BHP’s leadership, as he continues to build on the organization’s strong legacy of scientific excellence, impactful research, and capacity development in Botswana and beyond.

Please join us in congratulating Dr. Gaerolwe Masheto on his executive appointment.